Results 261 to 270 of about 93,014 (296)
Association of pruritus with comorbidities and survival in chronic kidney disease: a narrative review of the pre-difelikefalin era literature. [PDF]
Ren FailSaucereau J +5 more
europepmc +1 more source
Lebrikizumab ADvocate1 and 2 Monotherapy and ADjoin (Long-Term) Trials: Use of Topicals Therapies. [PDF]
Dermatol Ther (Heidelb)Stein-Gold L +7 more
europepmc +1 more source
Acquired perforating dermatosis associated with uremic pruritus treated with dupilumab monotherapy: A case report. [PDF]
JAAD Case RepMubarak S +4 more
europepmc +1 more source
PD‐L1‐Inhibitor‐Associated Hidradenitis Suppurativa
Journal of Cutaneous Pathology, EarlyView.
Annie Jin +2 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Clinics in Liver Disease, 1993
Why do patients with cholestasis itch? The answer to this fundamental question is unknown. It is inferred that substances that accumulate in plasma and other tissues, as a result of cholestasis, cause pruritus; however, the specific nature of the substances and the mechanism by which they cause pruritus has not been discerned.
E A, Jones, N V, Bergasa
openaire +3 more sources
Why do patients with cholestasis itch? The answer to this fundamental question is unknown. It is inferred that substances that accumulate in plasma and other tissues, as a result of cholestasis, cause pruritus; however, the specific nature of the substances and the mechanism by which they cause pruritus has not been discerned.
E A, Jones, N V, Bergasa
openaire +3 more sources
Current Treatment Options in Gastroenterology, 1999
The treatment of patients with pruritus of liver disease poses a challenge to the clinician. Resins (cholestyramine or colestipol) in quantities of 4 to 16 grams a day should be the initial agents used. In those who remain refractory, diphenhydramine should be added, although sedation may limit the use of higher doses.
openaire +2 more sources
The treatment of patients with pruritus of liver disease poses a challenge to the clinician. Resins (cholestyramine or colestipol) in quantities of 4 to 16 grams a day should be the initial agents used. In those who remain refractory, diphenhydramine should be added, although sedation may limit the use of higher doses.
openaire +2 more sources
Dermatologic Clinics, 2012
Health-related quality of life (QoL) is a patient-reported outcome that describes the impact of the disease in question to all aspects of persons' life, including psychosocial, emotional, physical, and functional impact. As such, health-related QoL is particularly relevant in conditions that have no physical signs and need to rely on patient reports to
openaire +2 more sources
Health-related quality of life (QoL) is a patient-reported outcome that describes the impact of the disease in question to all aspects of persons' life, including psychosocial, emotional, physical, and functional impact. As such, health-related QoL is particularly relevant in conditions that have no physical signs and need to rely on patient reports to
openaire +2 more sources
The International Journal of Artificial Organs, 2006
Renal itch is a localized or generalized itch, affecting patients with chronic renal failure, where there is no primary skin disease and no systemic or psychological dysfunction that might cause pruritus. Uremic pruritus (UP) is an unpleasant sensation, rarely appearing in earlier stages of chronic kidney disease.
G C, Kosmadakis, N, Zerefos
openaire +2 more sources
Renal itch is a localized or generalized itch, affecting patients with chronic renal failure, where there is no primary skin disease and no systemic or psychological dysfunction that might cause pruritus. Uremic pruritus (UP) is an unpleasant sensation, rarely appearing in earlier stages of chronic kidney disease.
G C, Kosmadakis, N, Zerefos
openaire +2 more sources